Gastroenterologists’ perspectives of high-dose dual therapy for Helicobacter pylori infection in China: Results of a China survey

This study investigates the knowledge of the high-dose dual therapy (HDDT) in the eradication of Helicobacter pylori (H pylori) infection among gastroenterologists in China. A survey was conducted among gastroenterologists in China using the “Questionnaire Star,” and the questionnaire link was sent by WeChat. Descriptive methods were used for statistical analysis. A total of 863 valid questionnaires were collected. The awareness rate of HDDT was 96.5%, and the clinical utilization rate was 69.1%.12.4%, 29.9%, and 25.6% gastroenterologists chose HDDT for the first-line, rescue and refractory treatment of H pylori infection. Amoxicillin was the most commonly used antibiotic in HDDT, followed by clarithromycin, furazolidone, levofloxacin, metronidazole, cefuroxime and tetracycline. Potassium-competitive acid blockers (51.8%) were the most commonly acid inhibitors in high-dose double therapy, followed by proton pump inhibitors and H2-receptor blockers. Most gastroenterologists believed that high-dose double therapy would become the main method of first-line and rescue treatment of H pylori infection. HDDT maybe the main treatment of H pylori eradication, but the application of the HDDT among gastroenterologists in China is insufficient. Better education should be carried out in future to improve the ability of gastroenterologists to standardize the treatment of H pylori infection.